TCTR20211207004CompletedPhase 4
A randomized, double blinded, split-face study of efficacy and safety of topical 0.05% Oxymetazoline on post acne erythema
/A0 sites30 target enrollmentStarted: December 7, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
Our study demonstrated that the OxH 0.05% solution is well-tolerated, safe, and effective for reducing PAE without a rebound effect. We proposed that this over-the-counter drug for nasal congestion could be an alternative treatment for PAE.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to 45 Years (—)
- Sex
- All
Inclusion Criteria
- •1. Subjects aged 18-45 years diagnosed by a dermatologist for mild to severe post acne erythema according to Clinician erythema assessment criteria.
- •2. Subjects who are informed in detail about the research study and express their interests in participation.
- •3. Subjects with redness scores from the VISIA differed by no more than 10% on both sides of the face.
Exclusion Criteria
- •1. Subjects with a history of rosacea or other active dermatitis on the treatment site. 2. Previously known allergic reaction to oxymetazoline 3. Subjects with a past medical history of hypertension, asthma, cardiovascular disease, cerebrovascular disease, vascular disease, close angle glaucoma, hypotension, or postural hypotension. 4. Female subjects who are currently in pregnancy or breastfeeding 5. Subjects who had previously treated post acne erythema with topical medications such as azelaic acid, or other facial procedures such as lasers, injections, or any chemical treatment within three months before study enrollment.
Investigators
Similar Trials
Completed
Phase 2
Hydroxychloroquine Administration for Reduction of PexophagyZellweger SyndromePeroxisome Biogenesis DisordersNCT03856866The Hospital for Sick Children3
Completed
Not Applicable
Effect of 1.5% Potassium Oxalate on the Control of Tooth Sensitivity and Color Change After Home BleachingDentin SensitivityNCT05028335Universidade Federal do Para50
Unknown
Phase 2
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive TreatmentSquamous Cell Carcinoma of Skin DifferentiatedBasal Cell CarcinomaNCT04929535Lawson Health Research Institute51
Active, not recruiting
Phase 1
PROTECT: studio randomizzato con idrossiclorochina vs osservazione per la prevenzione e il trattamento precoce della malattia da coronavirus (COVID-19)Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patientsGroup 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situationMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001501-24-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS2,300
Completed
Phase 2
A Pilot Study of Oxaloacetate in Subjects With Treated PDParkinson's DiseaseNCT01741701University of Kansas Medical Center33